SLC6A14 belongs to the SLC6 family, a group of sodium- and chloride-dependent transporters that also includes the well-known serotonin and dopamine transporters targeted by antidepressants. What sets SLC6A14 apart is its extraordinary breadth of substrate specificity. First cloned and functionally characterized by Sloan and Mager in 1999, the protein moves a wide spectrum of neutral and cationic amino acids across the plasma membrane, coupling each transport cycle to the inward flow of sodium and chloride ions. Later work established that it also transports beta-alanine and even carnitine, expanding its functional repertoire beyond standard protein building blocks. Because it concentrates substrates against steep gradients, SLC6A14 can accumulate amino acids inside cells to remarkably high levels, a property that has made it attractive both physiologically and pharmacologically.

Structural insights have come indirectly, largely through crystal structures of bacterial and human relatives in the neurotransmitter-sodium-symporter family, which revealed the alternating-access mechanism by which these proteins shuttle substrates across the membrane. Recent biochemical work has refined the picture for SLC6A14 itself. Studies of its pre-steady-state kinetics documented a rapid turnover rate and swift substrate translocation, and a 2025 analysis showed that the charge of the transported substrate determines the sodium-coupling stoichiometry of the transporter. Equally important is the question of how the protein reaches the cell surface in the first place. Research over the past several years has traced a trafficking route in which SLC6A14 exits the endoplasmic reticulum through a specific interaction with SEC24C, a component of the COPII coat complex, and depends on the heat shock protein HSP90 for proper delivery to the plasma membrane. In cancer cells, phosphorylation of SEC24C by the AKT kinase controls this trafficking, linking transporter surface abundance directly to growth-factor signaling.

The clearest disease signals, however, emerge in the gut. Genome-wide association studies and expression analyses have repeatedly flagged SLC6A14 in inflammatory bowel disease. Early transcriptional profiling of ulcerative colitis patients identified the gene among a handful of mucosal transcripts that distinguish inflamed tissue, and more recent integrative bioinformatics studies using weighted gene co-expression network analysis and machine learning have proposed SLC6A14 as a candidate diagnostic biomarker for ulcerative colitis. Mechanistic studies in cell and animal models have begun to explain how an amino acid transporter could fuel inflammation. In 2022, researchers reported that SLC6A14 facilitates epithelial cell ferroptosis, an iron-dependent form of cell death, via a C/EBPbeta-PAK6 signaling axis in ulcerative colitis. The following year, a separate team showed that the transporter promotes disease progression by facilitating NLRP3 inflammasome-mediated pyroptosis, another inflammatory cell death pathway. In models of colitis induced by dextran sulfate sodium and TNBS, altered SLC6A14 expression has been tied to intestinal epithelial injury.

Therapeutic angles are also taking shape in this inflammatory context. A 2025 study found that baicalin, a flavonoid compound, inhibited cell apoptosis, inflammation, and ferroptosis in ulcerative colitis by influencing Sp1-mediated transcription of SLC6A14. In Crohn’s disease, alpha-methyl-tryptophan, a tryptophan derivative long used as a transport inhibitor, was reported to suppress SLC6A14 expression and exhibit immunomodulatory effects. These findings suggest that damping the transporter’s activity, either directly or at the level of gene expression, may quiet the metabolic and inflammatory cascades that drive chronic intestinal injury, though the authors of the review caution that SLC6A14’s role appears to be context-dependent rather than uniformly protective or harmful.

Cystic fibrosis adds a different dimension. People with cystic fibrosis carry mutations in the CFTR chloride channel, and the severity of their gastrointestinal symptoms, including the often life-threatening neonatal condition meconium ileus, varies enormously between patients even with similar CFTR mutations. Modifier genes are thought to explain much of this variability. In 2012, a large genetic study of meconium ileus susceptibility identified multiple apical membrane constituents, SLC6A14 among them, as associated with the condition. Subsequent work confirmed that the transporter modifies the primary cystic fibrosis defect in fluid secretion, and a 2026 study traced this modifier effect to distinct regulatory elements controlling SLC6A14 expression. The mechanism likely hinges on the transporter’s influence on intestinal fluid handling, since SLC6A14 sits in the same apical membrane neighborhood as CFTR and the cGMP-dependent protein kinase II pathway that governs electrolyte and water secretion in the gut.

Perhaps the most striking story, and the one with the most direct translational momentum, involves digestive system cancers. SLC6A14 was first linked to colorectal cancer in 2005, when researchers documented upregulation of the transporter in human colorectal tumors and metastases. Later studies showed that the Wnt signaling pathway, a central driver of colon tumorigenesis, targets SLC6A14 and that the transporter functions as a tumor promoter in the colon. Aberrant SLC6A14 expression has been shown to enhance the JAK2/STAT3 signaling pathway, driving proliferation and metastasis in colorectal cancer, while blockade of the transporter suppressed tumor growth in preclinical models. In gastric cancer, depleting SLC6A14 was reported to induce amino acid starvation that curbed epithelial-mesenchymal transition and metastasis by perturbing the PI3K/AKT/mTORC1 pathway, one of the central nutrient-sensing circuits in cells.

Pancreatic ductal adenocarcinoma, one of the deadliest human malignancies, has become a particular focus. Transcriptomic and immunohistochemical profiling established that SLC6A14 is expressed in pancreatic tumors, and a 2016 pharmacological study identified the transporter as an effective drug target for pancreatic cancer. Genetic evidence followed: deletion of Slc6a14 in the KPC mouse model of spontaneous pancreatic cancer reduced tumor growth and metastatic spread and improved survival. Recent work has elaborated the metabolic logic behind these observations. In 2025, researchers reported that SLC6A14-mediated glutamine uptake promotes activation of a SYTL4-CXCL8 signaling axis that drives gemcitabine resistance and immune evasion in pancreatic cancer. A 2026 study in Gut showed that SLC6A14-mediated carnitine uptake from PPARgamma-positive cancer-associated fibroblasts promotes pancreatic cancer recurrence, illustrating how the transporter connects tumor cells to their metabolic microenvironment. Combined approaches that target SLC6A14 alongside autophagy and macropinocytosis, the scavenging pathways that pancreatic tumors rely on, are now being explored to enhance therapeutic efficacy.

What makes SLC6A14 especially interesting as a drug target is that it can be exploited in more than one direction. Blocking the transporter starves tumors of the amino acids they need to sustain rapid proliferation, while co-opting it offers a delivery route. Because the transporter accepts a broad range of substrates, chemotherapeutic agents and nanoparticles have been conjugated to carnitine or amino acid-like ligands to hitch a ride into cancer cells. Studies have demonstrated dual targeting of OCTN2 and ATB0,+ with l-carnitine-conjugated nanoparticles to deliver drugs for colon cancer, ATB0,+-targeted liposomes that enter cells through endocytosis for pancreatic cancer therapy, and nanoparticles designed to reset the amino acid metabolism of cancer cells for enhanced anticancer effects. The transporter’s high concentrating capacity means that even moderate surface expression can support substantial intracellular drug accumulation, a pharmacological advantage that few transporters offer.

The review by Xia and colleagues also situates SLC6A14 within a broader metabolic landscape. Earlier genetic studies had associated the gene with obesity, and mouse work has linked SLC6A14 deficiency to obesity, fatty liver, and metabolic syndrome under high-fat diet conditions, hinting at roles in systemic energy homeostasis that extend beyond the digestive tract. Tryptophan metabolism, increasingly appreciated as a bridge between gut physiology and brain signaling, adds another layer, since SLC6A14 transports tryptophan and its derivatives. The authors acknowledge that many open questions remain, including how the transporter’s expression is regulated in different disease states, how its genetic variation modifies clinical outcomes, and whether selective inhibitors can achieve therapeutic windows without disrupting normal amino acid nutrition. But the convergence of genetic associations, mechanistic pathways, animal models, and early delivery technologies makes a consistent case: a transporter once studied mainly for its unusual substrate range is now a credible candidate for biomarker development and targeted intervention across inflammatory bowel disease, cystic fibrosis, and gastrointestinal cancers alike.

Subject of Research: Role of the amino acid transporter SLC6A14 in inflammatory bowel disease, cystic fibrosis, and digestive system cancers

Article Title: Emerging roles of SLC6A14 in digestive system diseases: from amino acid transport to therapeutic targeting

Article References: Xia, Q., Sun, J., Yu, Q., Li, J., Zhou, B., & Zhu, L. (2026). Emerging roles of SLC6A14 in digestive system diseases: from amino acid transport to therapeutic targeting. Molecular Biology Reports, 53(1), Article 1613. https://doi.org/10.1007/s11033-026-12731-9

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12731-9

Keywords: SLC6A14, amino acid transport, solute carrier, inflammatory bowel disease, ulcerative colitis, Crohn's disease, cystic fibrosis, colorectal cancer, gastric cancer, pancreatic cancer, mTOR signaling, drug delivery

The study, led by Dr Elena Rainero, a Senior Lecturer at the University of Sheffield and based at the Sheffield Centre for Cancer Research, focused on two of the most aggressive and hard-to-treat cancers: breast cancer and pancreatic cancer. Both are characterised by tumours encased in a thick protective scaffold of connective tissue known as the extracellular matrix. In these cancers, this scaffolding is no minor component of the disease. It can make up as much as 90 per cent of the tumour’s total mass, forming a dense, fibrous barrier that severely restricts the blood vessels running through it.

That restriction has long posed a biological puzzle. Blood supply delivers glucose, the primary source of energy for cells in the body, along with the oxygen and nutrients that growing tissue requires. If a tumour’s scaffold chokes off that supply, the cancer cells inside should, in principle, be starved of fuel and die. Clinically, however, these nutrient-deprived tumours do not die. They persist, adapt, and often become more difficult to treat, spreading to other organs and taking root there. The Sheffield team set out to explain how.

The answer they uncovered centres on type I collagen, the most abundant protein in the human body and a major structural building block of the scaffolding that surrounds tumours. Rather than serving as passive scaffolding, the study found that this collagen actively participates in tumour survival. When glucose levels around the cancer cells drop, the collagen triggers signalling that allows the cells to switch to an alternative fuel supply: essential amino acids, the molecular building blocks that cancer cells need to construct the proteins required for growth and division.

The switch depends on a transporter protein called LAT1, which the researchers describe as functioning like an internal delivery system. LAT1 sits in the membrane of the cancer cell and pulls amino acids from outside the cell into its interior, sustaining the tumour through periods when its usual energy source is unavailable. In effect, the dense tissue that physically walls a tumour off from the bloodstream also provides the chemical signal that allows the tumour to change its diet and keep growing.

Laboratory tests on cellular models demonstrated that this vulnerability can be attacked. When the researchers blocked LAT1 transporters and simultaneously interrupted the cancer cells’ interaction with the surrounding collagen, the cells were cut off from the amino acids they had been importing and were starved of vital nutrients. That combined intervention offers a promising target for future therapies, particularly because it addresses a survival mechanism rather than the tumour cells themselves, which are prone to evolving resistance against direct attacks.

The clinical implications of the discovery extend beyond simply finding a new drug target. Dr Rainero noted that because cancer cells adapt so quickly, single treatments rarely eradicate a tumour entirely. Blocking the collagen-driven survival mechanism, she explained, could slow the growth and spread of cancer cells while making them more sensitive to existing treatments such as chemotherapy. A tumour that cannot switch fuel sources is a tumour under far greater metabolic stress, and one that standard therapies may finish off more effectively.

That sensitising effect could, in turn, allow clinicians to lower the doses of chemotherapy they administer. Dose reduction is far from a trivial benefit: severe and debilitating side effects are among the most burdensome aspects of cancer treatment, and lowering the amount of drug a patient receives while maintaining or improving effectiveness would meaningfully reduce that burden. According to the Sheffield team, the ultimate goal is to combine interference with the collagen-LAT1 pathway with existing therapies, starving aggressive tumours, stopping them from spreading, and preventing them from taking root elsewhere in the body, all with less toxic treatment regimens.

Scientifically, the study adds to a growing recognition that the tumour microenvironment is not merely background scenery but an active participant in cancer progression. The extracellular matrix, long studied for its physical role in blocking drug delivery and immune cell access, now appears to supply metabolic cues as well. Understanding how structural proteins such as type I collagen send signals that reprogramme cancer cell metabolism opens a new line of investigation into how tumours cope with the nutrient-poor conditions that their own growth creates, and why nutrient deprivation alone has so often failed as a therapeutic strategy.

The research, titled Collagen I promotes cancer cell survival via amino acid import and mTORC1/S6 activation, was published in PLOS Biology on 18 September 2026. As an observational study conducted on cells, it now awaits the translational work that will determine whether blocking LAT1 and disrupting collagen interactions can be achieved safely and effectively in patients. For cancers such as pancreatic ductal tumours, where treatment options remain limited and survival rates remain stubbornly poor, a strategy that turns the tumour’s own protective scaffold into a liability represents one of the more compelling new directions in cancer research.

Subject of Research: How type I collagen in the extracellular matrix helps breast and pancreatic cancer cells survive nutrient deprivation by switching to amino acid uptake via LAT1

Article Title: Starving cancer’s fuel source could boost treatment effectiveness

Article References: Starving cancer’s fuel source could boost treatment effectiveness. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cancer, type I collagen, extracellular matrix, LAT1, amino acid transport, pancreatic cancer, breast cancer, metabolism, chemotherapy, tumour microenvironment, University of Sheffield, PLOS Biology

For decades, L-serine was classified as a non-essential amino acid, meaning scientists assumed the brain could synthesize sufficient quantities internally through the phosphorylated pathway. Experiments in adult mice supported this view: deleting Phgdh, the gene encoding a key enzyme in the brain’s de novo serine synthesis, sharply reduces brain L-serine levels, indicating that local production dominates in mature animals. Yet the new work, led by Akshay K. Tiwari and Herman Wolosker of the Technion Israel Institute of Technology together with colleagues in Israel, the United States, and Switzerland, demonstrates that this picture is incomplete, particularly during early life. The developing brain, it seems, depends heavily on a supply line from the blood.

The researchers began by testing what happens when dietary serine disappears. Three-week-old mice were placed on a diet deficient in both serine and glycine, the latter restricted to prevent the two amino acids from replenishing one another through biochemical interconversion. After just ten days, high-performance liquid chromatography revealed that hippocampal L-serine had fallen by 45 percent and D-serine by 60 percent, with similar drops in the cerebral cortex. Serum serine and glycine also declined, confirming that the diet had genuinely restricted the amino acids reaching the brain. Because D-serine is manufactured inside the brain from L-serine by the enzyme serine racemase, the result made one thing clear: dietary L-serine is a major determinant of brain D-serine levels, and by extension, of the signaling molecules that calibrate NMDA receptor activity.

The metabolic consequences extended far beyond serine itself. Targeted metabolomics showed widespread reprogramming in the cortex, liver, and kidneys, with reductions in the serine precursor phosphoserine, pyruvate, and alpha-ketoglutarate, and increases in metabolites such as acetyl-CoA, NADPH, and sedoheptulose 7-phosphate. Perhaps most concerning was the fate of sphingolipids, the fatty molecules that build cellular membranes. When serine becomes scarce, the enzyme serine palmitoyltransferase substitutes alanine in its condensation reaction, producing 1-deoxysphinganine and, ultimately, a family of atypical lipids called 1-deoxysphingolipids. These compounds are cytotoxic and are known culprits in hereditary sensory and autonomic neuropathy type 1 and diabetic neuropathy. In the serine-deprived mice, the brain alanine-to-serine ratio doubled, and sphingolipidomic analysis revealed a striking accumulation of 1-deoxydihydroceramide species in the hippocampus. Gene expression shifted as well, with circadian rhythm genes such as Bmal1, Cry1, Per2, and Dbp downregulated, and several endothelium-enriched genes, including Cldn5 and Mfsd2a, altered alongside them.

Having established that blood-borne serine matters, the team set out to find which transporter ferries it across the blood-brain barrier. Two endothelial serine transporters, SLC38A5 and SLC1A4, were already known, but deleting them reduces brain L-serine by only 15 to 20 percent and 10 percent respectively, leaving a gap too large to explain the dietary effects. Mining RNA sequencing datasets and a human brain microvessel proteomics database, the researchers identified SLC38A2, also called SNAT2, as a strong candidate. This broad-spectrum neutral amino acid transporter of the system A family was known to move serine, alanine, glutamine, and other substrates in vitro, but its physiological role at the blood-brain barrier had never been defined. To settle the question, the team created mice in which Slc38a2 was selectively deleted from endothelial cells by crossing floxed animals with Tie2-Cre lines, then confirmed the deletion in purified brain microvessels by western blot.

The knockout animals told a remarkably selective story. Untargeted metabolomics of the cortex and hippocampus of eleven-day-old pups revealed that total serine was the only metabolite consistently reduced, with its precursor phosphoserine dropping in parallel; no other SLC38A2 substrate was measurably affected. HPLC analysis confirmed that both hippocampal L-serine and D-serine declined in the knockout pups, while serum amino acid levels remained normal, pointing to a brain-specific effect. When the researchers injected radiolabeled L-serine directly into the heart of the animals and measured its extraction into brain tissue ten seconds later, uptake in the knockout pups fell by 45 percent, while kidney uptake was unchanged. Fluorescein permeability assays confirmed that the barrier itself remained intact, ruling out nonspecific leakage.

Immunoelectron microscopy added a fascinating structural dimension. Gold particles labeling SLC38A2 decorated both the luminal membrane, facing the blood, and the abluminal membrane, facing the brain tissue, of endothelial cells in the neocortex, along with some intracellular signal. This dual placement means the transporter can, in principle, mediate flux in either direction depending on concentration gradients, and the isotope tracing experiments suggested exactly that. Whereas brain uptake of radiolabeled L-serine fell in the knockouts, the extraction of L-glutamine into the brain more than doubled, implying that glutamine transport through SLC38A2 normally runs in the opposite direction, from brain to blood. Stable isotope tracing with doubly labeled serine and uniformly labeled glucose confirmed that the brain’s internal serine synthesis from glucose was not compensating for the loss, and that glycine production was largely spared, with a cortical increase in glycine synthesis from glucose suggesting an adaptive mechanism to maintain glycine levels.

The developmental consequences were visible in the finest architectural details of the brain. Electron microscopic analysis of the dentate gyrus, a region undergoing intense synaptogenesis in the second week of life, revealed that asymmetric, predominantly glutamatergic synapses were selectively vulnerable in the knockout pups. The presynaptic vesicle clusters of these excitatory synapses were 25 percent smaller than in wild-type littermates, with the size distribution shifted toward smaller values, and the postsynaptic density area was similarly reduced. Symmetric, largely GABAergic synapses were unaffected, as was the total number of synapses of either type. Notably, markers of neurons and astrocytes, including NeuN, PSD-95, and GFAP, were unchanged, and bulk RNA sequencing detected only a handful of differentially expressed genes, indicating that the primary defect is metabolic rather than a broad developmental failure. Behavioral testing showed that negative geotaxis, grip strength, and limb suspension reflexes were all preserved, suggesting the pups are resilient to these subtle synaptic changes.

The story grew more nuanced as the mice matured. In juvenile and adult knockout animals, L-serine levels recovered, but D-serine remained persistently low, indicating that luminal SLC38A2 continues to import serine even when circulating concentrations fall after weaning. Meanwhile, glutamine and proline accumulated dramatically in the hippocampi of older knockout mice, implying that in adults, abluminal SLC38A2 normally exports these amino acids from the brain into the blood. Because glutamine and proline both serve as vehicles for ammonia disposal, the authors propose that SLC38A2 helps the aging brain rid itself of excess nitrogen, a function that becomes increasingly important as brain glutamine synthetase activity rises several-fold after the neonatal period. The finding echoes earlier work showing that other blood-brain barrier serine transporter deletions, including SLC38A5 and SLC1A4, also produce excitatory synaptic abnormalities, though the SLC38A2 phenotype proved milder, hinting that additional serine transporters partially compensate.

The therapeutic implications are already taking shape. On one side, blocking luminal SLC38A2 could dampen D-serine synthesis in conditions marked by NMDA receptor overactivation, such as epilepsy and traumatic brain injury, where excess astrocytic D-serine contributes to synaptic damage. On the other, the transporter may represent a metabolic weak point in brain cancer: glioblastoma growth depends on dietary L-serine crossing the blood-brain barrier, and SLC38A2 is overexpressed in these tumors, raising the prospect that selective inhibitors could starve the malignancy of an essential building block. Intriguingly, SLC38A2 expression is reduced in the dorsolateral prefrontal cortex of people with schizophrenia, a disorder closely tied to NMDA receptor hypofunction, opening a possible link between vascular amino acid transport and psychiatric disease. The authors caution that SLC38A2 is a contributor to brain serine import rather than necessarily the sole or dominant transporter, and that future work combining deletions of multiple endothelial serine transporters will be needed to complete the picture. Still, the study rewrites a fundamental rule of neurochemistry: the developing brain is not a self-sufficient serine factory, but an organ that relies on its vascular gatekeepers, and on the diet itself, to build the synapses that make thought possible.

Subject of Research: Role of the endothelial blood-brain barrier transporter SLC38A2 in brain L-serine and D-serine homeostasis and synapse development

Article Title: Endothelial SLC38A2 controls brain D-serine homeostasis and synapse development

Article References: Tiwari, A. K., Lahkar, A., Sajrawi, C., Hussein, Y., Majcher, A., Bonelli, S., Agranovich, B., Abramovich, I., Stern, S., Chaudhry, F. A., Hornemann, T., Radzishevsky, I., & Wolosker, H. (2026). Endothelial SLC38A2 controls brain D-serine homeostasis and synapse development. iScience, 29(10), Article 117487. https://doi.org/10.1016/j.isci.2026.117487

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117487

Keywords: SLC38A2, blood-brain barrier, L-serine, D-serine, NMDA receptors, synapse development, amino acid transport, sphingolipids, metabolomics, glioblastoma, endothelial cells, brain development